Join to View Full Profile
6001 North MayfairSpokane, WA 99208
Phone+1 509-462-2273
Fax+1 509-462-2275
Dr. Chaudhry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1993 - 1996
Christian Medical College LudhianaClass of 1989
Certifications & Licensure
ID State Medical License 2019 - 2026
WA State Medical License 1999 - 2026
IA State Medical License 1995 - 2000
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 2008 Sep 24
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsNemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20 - 1 citationsGenomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01 - 1 citationsDerazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer
JNCI Cancer Spectrum. 2024-04-30
Press Mentions
American Oncology Network Physicians Research Presented at 64th ASH Annual Meeting & ExpositionDecember 14th, 2022- Vial Announces Dr. Arvind Chaudhry of Summit Cancer Centers as a New Member of Vial’s Oncology CRO Advisory BoardJuly 27th, 2022
- American Oncology Network Physicians Research Presented at ASCO22June 13th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
